

Environmental, Social and Governance Report

環境、社會及管治報告

2021



股份代號 Stock Code: 00455 (於開曼群島註冊成立之公司)
(Incorporated in the Cayman Islands with limited liability)

CONTENTS

目錄

2	ABOUT THIS REPORT	關於本報告
2	Basis of Preparation	編製依據
2	Environmental, Social and Governance Strategies	環境、社會及管治策略
3	Stakeholders Identification	識別持份者
4	Identification of Material Issues	重大事宜識別
4	Confirmation	確認
4	Approval	批准
5	THE MATERIAL ESG ISSUES	重大環境、社會及管治事宜
6	A. Environmental	A. 環境
6	A1 Emissions	A1 排放物
11	A2 Use of Resources	A2 資源使用
14	A3 The Environment and Natural Resources	A3 環境及天然資源
14	B. Social	B. 社會
14	B1 Employment	B1 僱傭
15	B2 Health and Safety	B2 健康與安全
16	B3 Development and Training	B3 發展及培訓
16	B4 Labour Standards	B4 勞工準則
17	B5 Supply Chain Management	B5 供應鏈管理
17	B6 Product Responsibility	B6 產品責任
19	B7 Anti-corruption	B7 反貪污
20	B8 Community Investment	B8 社區投資
21	AWARDS AND RECOGNITIONS	獎項與嘉許
22	Stakeholders' Feedback	持份者的意見回饋

ABOUT THIS REPORT

Tianda Pharmaceuticals Limited (the Company) and its subsidiaries (collectively the Group) is hereby pleased to issue this Environmental, Social and Governance Report (the/this ESG Report). The Group implements the three strategic policy objectives: development of Traditional Chinese medicine (TCM) as its foundation, development of innovative drugs and medical technologies, as well as development of high-quality medical and healthcare services. It is committed to becoming a leading pharmaceutical enterprise that sets its footholds in China while seeking to expand its presence worldwide.

Basis of Preparation

This ESG Report is prepared in accordance with Appendix 27 to the Rules Governing the Listing of Securities (the Listing Rules) on The Stock Exchange of Hong Kong Limited (the Stock Exchange) – “Environmental, Social and Governance Reporting Guide” (the ESG Guide). The Group adheres to the principles of materiality, quantitative, balance and consistency to report on its Environmental, Social and Governance (ESG) measures and performances.

This ESG Report covers the ESG activities of the Group during the period from 1 April 2020 to 31 March 2021 (the Reporting Period). The purpose is to publicly report to shareholders, employees, customers, partners and stakeholders regarding the practice, performance and development of the Group in fulfilling environmental policies and corporate social responsibility during the Reporting Period.

Information regarding corporate governance has been addressed in the 2021 annual report in pursuance of Appendix 14 of the Listing Rules.

ESG STRATEGIES

In line with the ESG Guide, the Board of Directors of the Company (the Board) has overall responsibility for the Group's ESG strategy and reporting. The Board evaluates and determines the ESG-related risks of the Group, and ensures an appropriate ESG risk management and internal control systems are in place that can effectively identify risks.

The Group has established an ESG working team, which consists of management and employees from each functional department. The team is responsible for planning of the Group's sustainable development, monitoring the implementation of the relevant policies and writing the ESG Report. The Board reviews, analyzes and evaluates the Group's ESG report annually, and will take appropriate measures and make recommendations in a timely manner regarding the key risks and policies implementation. The implementation of such measures is carried out by management and all relevant departments under the supervision of the Board.

The Board believes that sound ESG performance is critically important to the sustainable development of the Group's business and the community. The Board is committed not only to achieving a healthy financial position, but also to promoting environmental protection, social responsibility and effective corporate governance.

關於本報告

天大藥業有限公司（本公司）及其附屬公司（合稱本集團）欣然發佈本環境、社會及管治報告。本集團以發展中醫藥產業為基礎，發展創新藥物和醫療科技，發展優質醫療和保健服務，致力成為立足中國，輻射全球的領先醫藥企業。

編製依據

本環境、社會及管治報告乃根據香港聯合交易所有限公司（聯交所）證券上市規則（上市規則）附錄27《環境、社會及管治報告指引》而編製。本集團遵守重要性、量化、平衡及一致性準則申報其環境、社會及管治措施及表現。

本環境、社會及管治報告涵蓋2020年4月1日至2021年3月31日期間（本報告期間）有關本集團的環境、社會及管治工作。旨在向股東、員工、客戶、合作夥伴及持份者公開報告本集團在本報告期間履行環境政策及企業社會責任方面的實踐、績效與發展情況。

有關企業管治的資料已根據上市規則附錄十四於2021年度年報中載述。

環境、社會及管治策略

跟《環境、社會及管治報告指引》的要求一致，本公司董事會對本集團環境、社會及管治策略及匯報承擔全部責任。董事會評估及釐定本集團有關環境、社會及管治方面的風險，並確保設有合適的環境、社會及管治風險管理及內部監控系統，能有效辨識風險。

本集團已成立環境、社會及管治工作小組，由各個職能部門的管理人員及僱員組成。小組負責本集團可持續發展的規劃、監督相關政策的實施，以及撰寫環境、社會及管治報告。董事會每年對本集團的環境、社會及管治報告進行審閱、分析及評估，並就當中主要風險及落實政策適時採取適當措施及作出建議。在董事會的監督下，這些措施的實施由管理層及所有相關部門貫徹執行。

董事會相信，良好的環境、社會及管治表現對本集團業務及社區的可持續發展至關重要。董事會不僅致力於實現穩健財務狀況，而且亦致力於推廣環境保護、社會責任及高效的企業管治。

In the future, through continuous improvement on internal corporate governance structure; enhancement on internal control systems; strengthening risk management of ESG matters, the Group will further raise the standard and efficiency of its ESG governance. The Group will also dedicate more resources to reducing the impacts on environment caused by the operation to grasp the opportunities brought by sustainable development.

Stakeholders Identification

Stakeholders' participations are critical factors for establishing the Group's ESG strategies. The Group has communicated with relevant stakeholders to understand and prioritize their concerns and expectations. The Group has evaluated, and responded to their feedbacks in order to improving the Group's ESG performance

With the support from business partners, customers and other stakeholders, the Group will lead the industry to a future where development is more sustainable. Ultimate goal is to achieve a win-win situation and create value to the Group, various stakeholders and the community.

未來，通過不斷完善企業內部管治結構、加強內部管控系統、加強環境、社會及管治事宜的風險管理，本集團將提升在環境、社會及管治方面的管治水平及管治效率；並會持續投放更多資源，減少營運對環境所造成的影響，從而抓緊可持續發展帶來的機遇。

識別持份者

持份者的參與是制定環境、社會及管治策略的關鍵要素。本集團與各有關持份者溝通，從而理解及優先考慮他們的關注與期望。本集團亦已分析及回應他們的反饋，從而提升本集團環境、社會及管治的表現。

在業務夥伴、客戶及其他持份者的支持下，本集團將帶領行業邁向更符合可持續發展的未來。最終目標達致雙贏，為本集團、各持份者以及社區創造價值。

Stakeholders 持份者

Communication channels 溝通渠道

Concerns and expectation 關注與期望

Shareholders and Investors
股東及投資者

General meeting
股東大會
Announcements
公告
Company's website
公司網頁
Press releases
媒體發報

Return on investments
投資回報
Transparent disclosures
公開透明的披露

Government / Regulatory Authority
政府/監管機構

Regular conversation with regulatory authorities
定期與監管機構對話
Inspection and supervision
檢查督查
Communication with local departments
與當地部門交流

Compliance with laws and regulations
遵守法律及法規
Proper tax payment
按時足額納稅
Production safety
安全生產
Cultivation of local economic development
促進地方經濟發展

Customers
顧客

Website, brochures, annual reports and other published information
網站、宣傳冊、年報及已發佈的其他資料
Email and customer service hotline
電郵及客戶服務熱線
Feedback forms
意見反饋表

Safe and high quality products and services
安全和優質的產品及服務
Consumer right protection
保護消費者權益
Protect customer privacy
保護客戶私隱
Fair and reasonable pricing
公平和合理定價

Stakeholders 持份者	Communication channels 溝通渠道	Concerns and expectation 關注與期望
Suppliers 供應商	Business meetings, supplier conferences, phone calls, interviews 業務會議、供應商會議、電話、面談 Review and assessment 審核及評估 Tendering process 投標流程	Long-term business relationship 長期營銷關係 Fair and reasonable pricing 公平和合理定價
Employee 員工	Employee trainings 員工培訓 Internal publication and intranet of the Company 公司內刊和內聯網 Performance assessments and evaluations 績效評估及考核 Regular staff individual interview 定期員工單獨約談	Protect the rights of employees 保障員工權益 Career development and training opportunities 職業發展和培訓機會 Create a good working environment 營造良好的工作環境
Community 社區	Company's website 公司網頁 Social media platforms 社交媒體平臺 Charity and social investment 慈善及社區投資	Community participations 社區參與

Identification of Material Issues

The Group's ESG working team identifies relevant ESG issues and assesses their materiality to the Group's business as well as the Group's stakeholders by the way of materiality assessment. The materiality assessment has based on the continuous discussions and communications with the stakeholders. Through various abovementioned channels, the Group understands expectations from major stakeholders.

After our assessments of (1) feedbacks from stakeholders; (2) the core business model and operation procedures of the Group; and (3) the statutory requirements for information disclosure, the Group has identified 16 key issues on sustainable development related to its operation (the Material ESG Issues).

Disclosures relating to the Material ESG Issues identified have been included and focused on this ESG Report pursuant to the requirements of the ESG Guide.

Confirmation

The information documented in this ESG Report is sourced from official documents, statistical data, and management and operation information of and collected by the Group in accordance with relevant internal policies. The Group has established internal controls and a formal review process to ensure that any information presented in this ESG Report is as accurate and reliable as possible.

Approval

After management review, this ESG Report was approved by the Board on 22 October 2021.

重大事宜識別

本集團的環境、社會及管治工作小組，通過重要性評估的方式，識別出相關的環境、社會及管治事宜，並評估其對本集團業務以及本集團持份者的重要性。重要性評估乃基於與持份者的持續討論及溝通，本集團透過上述多種途徑了解主要持份者不同期望。

經過我們評估(1)持份者的反饋；(2)本集團自身的核心業務模式和運營流程；以及(3)法定信息披露的要求後，本集團識別出16項與其運營相關的可持續發展關鍵事宜（重大環境、社會及管治事宜）。

有關已發現的重大環境、社會及管治事宜的披露已根據《環境、社會及管治報告指引》載入本環境、社會及管治報告作重點匯報。

確認

本環境社會及管治報告引用的資料來自本集團的官方文件、統計數據、本集團根據有關內部政策收集的管理及營運資料。本集團已制訂內部監控及正式審核程序，以確保於本環境、社會及管治報告呈列的任何資料均盡可能準確可靠。

批准

本環境、社會及管治報告經管理層確認後，於2021年10月22日獲董事會通過。

THE MATERIAL ESG ISSUES

The table below shows the Material ESG Issues which were determined to be material to the Group, together with the two subject areas (Subject Areas) and various aspects of each Subject Area (Aspects) on the ESG Guide to which they relate, based on the assessment performed by the ESG working team. This ESG Report mainly covers the policies, measures and performance of the Group's business in relation to these issues, for the period from 1 April 2020 to 31 March 2021 (the Reporting Period):

重大環境、社會及管治事宜

下表列示根據環境、社會及管治工作小組進行的評估，被認為對本集團而言屬重大的環境、社會及管治事宜，以及有關事宜所涉及的環境、社會及管治報告指引的兩個主要範疇(主要範疇)及每個主要範疇的多個層面(層面)。本環境、社會及管治報告涵蓋2020年4月1日至2021年3月31日(本報告期間)，本集團業務的政策、措施及表現：

ESG Subject Areas and Aspects as set forth in the ESG Guide	The Material ESG Issues of the Group	《環境、社會及管治報告指引》所載的環境、社會及管治的主要範疇及層面	本集團的重大環境、社會及管治事宜
A. Environmental			
A1 Emissions	Greenhouse gas and exhaust gas emissions management Wastewater treatment Solid waste treatment General waste management	A1 排放物	溫室氣體及廢氣排放管理 廢水處理 固體廢棄物處理 一般廢棄物管理
A2 Use of Resources	Use of energy Use of water Use of packaging materials	A2 資源使用	能源使用 用水 包裝物料使用
A3 The Environment and Natural Resources	Air quality	A3 環境及天然資源	空氣質素
B. Social			
B1 Employment	Labour practices	B1 僱傭	勞工常規
B2 Health and Safety	Workplace health and safety	B2 健康與安全	工作環境健康與安全
B3 Development and Training	Employee development and training	B3 發展及培訓	僱員發展及培訓
B4 Labour Standards	Anti-child and forced labour	B4 勞工準則	禁止童工及強制性勞動
B5 Supply Chain Management	Supply chain management	B5 供應鏈管理	供應鏈管理
B6 Product Responsibility	Product health and safety and labelling	B6 產品責任	產品健康與安全以及標籤
B7 Anti-corruption	Anti-corruption and money laundering	B7 反貪污	反貪污及洗黑錢
B8 Community Investment	Community programs and donation	B8 社區投資	社區計劃及捐款

A. ENVIRONMENTAL

The Group has established policies and management systems about environmental protection. All companies under the Group are required to strictly execute them in order to minimizing the impacts from operations to the environment.

The Group also proactively encourages its staff to protect the environment through trainings, educations and communications. Ultimately, all employees will adopt eco-responsible habit no matter in workplace or daily lives.

The Group always keeps itself up-to-date on developments in local legislation and standards for environmental protection and is committed to achieving a level of environmental standards that goes beyond compliance.

A1 Emissions

The Group strictly abides by its relevant laws and regulations in relation to pollutant emissions in the places of operation, where the relevant laws and regulations that have a significant impact on the Group mainly include the following:

- Environmental Protection Law of the People's Republic of China (the PRC);
- Atmospheric Pollution Prevention and Control Law of the PRC;
- Water Pollution Prevention and Control Law of the PRC; and
- Law of the PRC on the Prevention and Control of Environment Pollution by Solid Waste

During the Reporting Period, to the best of our knowledge and information, the Group did not find and was not aware of any incidents of non-compliance to the above relevant laws and regulations in relation to pollutant emissions.

The principal business of the Group are “Chinese medical business”, “Pharmaceuticals and medical technologies business” and “Medical and healthcare services” respectively. Among them, the “Chinese medical business” mainly engages in trading of Chinese medicine products, while “Medical and healthcare services” are the operation of Chinese medical clinics and the provision of Chinese medical services. These two businesses do not generate significant hazardous or non-hazardous emissions, wastes or pollutants.

A. 環境

本集團已制訂環境保護政策及管理制度，要求集團旗下各公司於營運中確切執行，力求將業務對環境的影響減至最低。

本集團亦透過培訓、教育及溝通積極鼓勵員工保護環境。最終讓所有員工無論在工作或日常生活中均能養成對生態環境負責任的習慣。

本集團時常保持自身緊跟當地環境保護立法及標準的最新發展，致力於實現高於合規程度的環境標準。

A1 排放物

本集團嚴格遵守其營運地之有關污染廢物排放的法律及規例，當中對本集團有重大影響的相關法律及規例主要包括下列所述：

- 《中華人民共和國環境保護法》；
- 《中華人民共和國大氣污染防治法》；
- 《中華人民共和國水污染防治法》；及
- 《中華人民共和國固體廢物污染環境防治法》。

於本報告期間，據我們所知及信息，本集團並未發現及察覺到任何違反上述有關污染廢物排放的法律及規例之情形。

本集團主要業務分別為“中醫藥業務”、“藥物和醫療科技業務”以及“醫療和保健服務”。當中，“中醫藥業務”主要從事中醫藥產品貿易銷售，而“醫療和保健服務”為經營中醫館，提供中醫診療服務，該兩項業務未有產生重大有害及無害排放、棄物或污染。

The “Pharmaceuticals and medical technologies business” involves in pharmaceuticals research and development and manufacturing and productions are performed by Tianda Pharmaceuticals (Zhuhai) Limited (Tianda Pharmaceuticals (Zhuhai)) and Yunnan Meng Sheng Pharmaceutical Co., Ltd. (Meng Sheng) (collectively the Two Manufacturing Subsidiaries).

The Group is very cautious in controlling the discharge of environmental pollutants in the production processes of pharmaceuticals. The exhaust gas, wastewater and solid waste (the Three Wastes) generated from the Group’s pharmaceutical production processes can all meet the requirements of the national emission standards, and the Three Wastes discharged are reduced to minimum level via efficient treatment systems and monitoring equipment.

Greenhouse gas and exhaust gas emissions management

The Group’s greenhouse gas (GHG) and exhaust gas emissions mainly come from carbon dioxide (CO₂) and exhaust gas generated during the production process respectively.

Our CO₂ emissions primarily come from the use of energy during pharmaceutical production (the CO₂ emissions data shown below is derived from the use of fuel in the production process – diesel), followed by consuming of energy in general daily business. The Group has developed various energy-saving initiatives to reduce the carbon footprint generated from consuming of energy in general daily business (please refer to the section “**A2 Use of Resources – Use of energy**” below).

The Group’s pharmaceutical production business accounts for the largest proportion of the Group’s overall CO₂ and exhaust gas emissions. In the production process, exhaust gas mainly comes from the boiler combustion, where deleterious substances mainly include sulfur dioxide (SO₂), nitric oxide (NO_x) and suspended particles (PM), as well as CO₂ generated from energy consumption during the production process (mainly including diesel). In order to reduce the environmental and ecological adverse effects of GHG and exhaust gas emissions, the Group has established and implemented the following management policies:

- Increase the height of the flue in accordance with the authorities’ regulations;
- Install PM dust arrester device;
- Clean chimney dust regularly to reduce dust emissions;
- Use relatively clean diesel, National VI Standard, as a fuel for production to reduce the CO₂ generated from the using of diesel;

“藥物和醫療科技業務”涉及藥物研發及生產，並由天大藥業(珠海)有限公司(天大藥業(珠海))及雲南盟生藥業有限公司(盟生藥業)(統稱兩家生產附屬公司)負責生產。

本集團非常謹慎地把控藥品生產環節中環境污染物的排放，通過有效的處理系統及監控設備，本集團藥品生產環節中產生的廢氣、廢水及固體廢棄物(三廢)均能滿足國家的各項排放標準，並嚴格做到三廢最小化污染物排放量。

溫室氣體及廢氣排放管理

本集團溫室氣體及廢氣排放主要分別來自生產過程中產生的二氧化碳及廢氣。

我們二氧化碳排放主要源自藥品生產時能源使用(下文二氧化碳排放數據是源自生產過程中使用的燃料 – 柴油)，其次是一般日常業務能源使用時所產生的二氧化碳。本集團已制訂多個節能措施，以幫助減少一般日常業務碳足跡(請參閱下文“**A2資源使用 – 能源使用**”章節)。

本集團藥品生產業務佔集團整體二氧化碳及廢氣排放比例最大，生產過程中主要有鍋爐燃燒產生廢氣排放，當中的有害物質主要是二氧化硫、氮氧化物及懸浮粒子，以及生產時能源使用(主要包括柴油)所產生的二氧化碳。為減少溫室氣體及廢氣排放對環境及生態帶來的不良影響，本集團設立和實施了以下各項管理政策：

- 按政府當局規定加高煙道高度；
- 安裝懸浮粒子捕塵裝置；
- 定期清潔煙囪灰塵，以減少煙塵排放量；
- 使用較為清潔的國VI標準的柴油作為生產用燃料，以助減少使用柴油而產生的二氧化碳；

- Regularly remove boiler scale in the flue pipe to improve thermal efficiency and reduce diesel consumption; and
- Engage independent professional institutions to conduct air and exhaust gas testing annually to ensure the exhaust gas emission in compliance with the national emission standards.

During the Reporting Period, our SO₂ and NO_x emission indicators were far below the national emission standards as per our own and environmental protection departments' random checking.

The followings are the GHG and exhaust gas emissions data of the Two Manufacturing Subsidiaries during the Reporting Period. During the financial year ended 31 March 2021, the Two Manufacturing Subsidiaries contributed about 75% consolidated revenue of the Group:

Emissions 排放物	Unit 單位	Period from 1 April 2020 to 31 March 2021 2020年4月1日至 2021年3月31日期間		Period from 1 April 2019 to 31 March 2020 2019年4月1日至 2020年3月31日期間	
		Emission Volume 排放量 Total 總計	Intensity* 密度* Per million HK\$ revenue 每百萬港元 收入	Emission Volume 排放量 Total 總計	Intensity* 密度* Per million HK\$ revenue 每百萬港元 收入
Greenhouse gas and exhaust gas emissions 溫室氣體及廢氣排放					
Carbon dioxide (CO ₂)	二氧化碳 metric ton 公噸	535	1.129	529	1.077
Sulfur dioxide (SO ₂)	二氧化硫 kg 千克	139	0.292	255	0.519
Nitric oxide (NO _x)	氮氧化物 kg 千克	422	0.889	866	1.762
Suspended particles (PM)	懸浮粒子 kg 千克	74	0.157	83	0.169

* Intensity is calculated by dividing the emission volume by the Group's total revenue during the Reporting Period.

Wastewater treatment

The wastewater generated by the Group mainly includes production wastewater from the manufacturing process of pharmaceuticals and employees' domestic wastewater. Those wastewaters generated from medicine manufacturing process contain various chemicals, so they must not be directly discharged. The Group has taken measures to ensure these wastewaters are properly treated and complies with the regulatory standard requirements. Wastewaters are then discharged via designated municipal waste sewage pipes.

The Group's two pharmaceutical production bases in Zhuhai and Kunming have installed wastewater treatment systems. The production wastewater and domestic wastewater generated in the production bases are processed by our sewage treatment systems to reach the standards (i.e. the "Integrated Wastewater Discharge Standard" and the "Wastewater Quality Standards for

- 定期對鍋爐煙管進行除水垢處理，提高熱效能，減少柴油使用量；及

- 每年定期聘請獨立專業機構進行空氣及廢氣檢測，以確保廢氣排放符合國家排放標準。

於本報告期間，經我們自己和環保部門隨機檢測，我們二氧化硫及氮氧化物排放指標均遠低於國家排放標準。

以下為兩家生產附屬公司於本報告期間溫室氣體及廢氣排放數據。於截至2021年3月31日止財政年度，兩間生產附屬公司貢獻集團綜合收入的75%：

* 密度的計算方式為本報告期間排放量除以本集團整體收入。

廢水處理

本集團產生的廢水主要包括在藥品生產製造過程中的生產廢水和員工的生活廢水。藥品製造過程產生的廢水含有各種化學物質，因此不可直接排放，本集團已採取措施確保這些廢水經過妥善處理，以符合法定標準要求，廢水再透過市政指定廢水管排出。

本集團在珠海市及昆明市的兩家製藥基地均設有污水處理系統。生產廢水和生活廢水經基地污水處理系統達標（即《污水綜合排放標準》以及《污水排入城鎮下水道水質標準》）、及檢驗合格後，排入市政污水管網，最後再經由市

Discharge to Municipal Sewers”) and pass the acceptance test before discharged into the municipal sewage pipe network. Finally, the wastewater is further processed in the municipal centralized sewage treatment systems. Our sewage treatment stations adopt advanced biological treatment processes, which mainly include Anaerobic/Anoxic/Oxic (A/A/O) process and Bioactive Carbon process. Wastewater are filtered by sedimentation, and undergone anoxic and anaerobic biochemical treatment, etc., to effectively reduce the pollutants contained in the wastewater (for examples, SS, COD, BOD5, ammonia nitrogen, total phosphorus, etc.) before the decomposition process, where the emission standards are complied with the national regulations.

The Group commissions qualified third-party institutions to conduct regular inspection yearly, and during the Reporting Period, the sewage discharge indicators were in accordance with national emission standards.

The followings are the wastewater emission data of the Two Manufacturing Subsidiaries during the Reporting Period:

Emissions 排放物	Unit 單位	Period from 1 April 2020 to 31 March 2021 2020年4月1日至 2021年3月31日期間		Period from 1 April 2019 to 31 March 2020 2019年4月1日至 2020年3月31日期間	
		Emission Volume 排放量 Total 總計	Intensity* 密度* Per million HK\$ revenue 每百萬港元 收入	Emission Volume 排放量 Total 總計	Intensity* 密度* Per million HK\$ revenue 每百萬港元 收入
Wastewater 廢水	metric ton公噸	20,782	43.812	29,428	59.877

* Intensity is calculated by dividing the emission volume by the Group's total revenue during the Reporting Period.

Solid waste treatment

The Group's solid wastes generated from the pharmaceutical production process primarily include two types, namely non-hazardous solid wastes and hazardous solid wastes.

The Group has taken a number of practical and effective measures to reduce the environmental burden of solid wastes and to maximise the utilisation of resources, such as:

- The approach for solid wastes treatment is to have centralized collection at first, and then sort by categories, and allocate appropriate storage space for temporary storage of the categorized wastes;
- Non-hazardous solid wastes are centralized stored in the designated locations, and are processed periodically and timely by the local sanitation department or outsourced services providers;

政污水處理系統集中處理。我們的污水處理站採用先進生物處理工藝，污水處理工藝主要是厭氧/缺氧/好氧工藝及生物活性碳工藝，廢水經過沉澱過濾、增氧及厭氧菌生物處理等，有效降低廢水中的污染物含量後(例如水中的懸浮物含量、化學需氧量、生物需氧量、氨氮、總磷等)進行分解處理，達到國家法規排放標準。

本集團每年定期委託具有資質的第三方進行檢測，而本報告期內污水排放指標均符合國家排放標準。

以下為兩家生產附屬公司於本報告期間廢水排放數據：

* 密度的計算方式為本報告期間排放量除以本集團整體收入。

固體廢棄物處理

本集團藥品生產製造過程所產生的固體廢棄物主要為兩類，無害固體廢棄物及有害固體廢棄物。

本集團為減少固體廢棄物帶來的環境負擔及實現資源的最大化利用採取了許多實際有效的措施，如：

- 固體廢棄物的處理方法為先集中收集，後分類處理，並配置合適的分類貯存場所暫存廢棄物；
- 無害固體廢棄物指定位置集中存放，經由當地環衛局或外判服務商定期及時清理處理；

- When the weekly processing volume of the non-hazardous solid waste exceeds the normal level, the dedicated department will investigate the reasons behind, and make recommendations and/or follow-up actions for control purpose;
 - In compliance with the national standards for storage and treatment of hazardous solid wastes, the hazardous solid wastes are properly packed and stored in designated storage areas, and are processed by qualified contractors in due course;
 - Recycles and reuses glass, cardboard, paper materials, metal, printing cartridges and batteries. Sets up collection facilities placed across factories; and
 - Sell the waste plastic, metallic and paper packaging materials to recyclers for comprehensive utilization.
- 當無害固體廢棄物每週處理量超出常規水平，專責部門會查找原因，並提交處理意見及或後續行動以進行控制；
 - 按照國家危險廢棄物的存儲標準，有害廢棄物均妥善封裝存放於指定貯存區，適時由合資格承辦商定時專項處理；
 - 回收玻璃、紙板、紙質材料、金屬、打印墨盒及電池再利用，並在工廠各處設置回收設施；及
 - 將廢棄塑膠、金屬、紙質包裝材料售予廢品回收商作綜合利用。

The followings are the solid waste data generated by the Two Manufacturing Subsidiaries during the Reporting Period:

以下為兩家生產附屬公司於本報告期間產生的固體廢棄物數據：

Emissions 排放物	Unit 單位	Period from 1 April 2020 to 31 March 2021 2020年4月1日至2021年3月31日期間		Period from 1 April 2019 to 31 March 2020 2019年4月1日至2020年3月31日期間	
		Emission Volume 排放量 Total 總計	Intensity* 密度* Per million HK\$ revenue 每百萬港元收入	Emission Volume 排放量 Total 總計	Intensity* 密度* Per million HK\$ revenue 每百萬港元收入
Solid waste 固體廢棄物					
Non-hazardous waste 無害廢棄物	metric ton 公噸	20	0.043	22	0.045
Hazardous waste 有害廢棄物	metric ton 公噸	3	0.007	11	0.022

* Intensity is calculated by dividing the emission volume by the Group's total revenue during the Reporting Period.

* 密度的計算方式為本報告期間排放量除以本集團整體收入。

General waste management

Other than the Three Wastes generated from the manufacturing and productions as mentioned above, general wastes are also generated from the Group's business, mainly consist of paper (for example office paper), as well as domestic wastes from the daily life of the employees. No substantial hazardous general wastes were produced by the Group during the Reporting Period.

The Group has launched a number of general waste management programs, including:

一般廢棄物管理

除了上述從生產製造過程中產生的三廢外，本集團業務中亦會產生的一般廢棄物，主要包括紙張（例如辦公室用紙）以及員工日常生活產生的生活垃圾。本集團於本報告期間並無產生任何重大有害的一般廢棄物。

本集團推出眾多一般廢棄物管理計劃，包括：

- Encourage the use of emails for internal and external communication so as to reduce paper consumption, and scanning the paper fax and physical mailing into electronic version for email delivery;
- Use paperless office automation system and human resources information system by encourage the use of electronic system for various internal approval processes and human resource information transmission, such as payment approval, contract approval and employee holiday approval, etc.;
- To encourage staff to reduce paper consumption by double-sided printing and reusing of papers printed on one side; and
- Collect domestic wastes separately and sell the recyclable wastes to the recycling station.

A2 Use of Resources

With the vision of helping to protect the planet and of incorporating environmental sustainability into its business functions and processes, the Group proactively seeks opportunities for increasing operating efficiency in order to reduce the use of resources. The Group also closely monitors the utilisation of resources and reports to senior management on this aspect of performance. Appropriate remedial actions to improve efficiency in the use of resources are taken whenever necessary.

Use of energy

The Group's energy use mainly consists of electricity (including both the production and the domestic use) and diesel (the fuel used in the production process).

In addition to the measures mentioned above in the section "**A1 Emissions – Greenhouse gas and exhaust gas emissions management**" to reduce GHG and exhaust gas emissions to achieve the saving of diesel consumption, in order to further achieve higher energy efficiency, the Group also implemented the following key initiatives to reduce the use of electricity during the Reporting Period:

- Use energy efficient electric appliances as far as possible;
- Maintain the air conditioning temperature of office at about 25°C; and
- Switch off or set to energy saving mode for electric appliances when they are not in use.

- 鼓勵對內及對外通訊儘量使用電子郵件以減少紙張消耗，及將紙質傳真或郵寄掃描成電子版進行電子郵件傳遞；
- 使用無紙化辦公自動化系統及人力資源資訊系統，鼓勵各項內部工作審批流程及人力資源資訊傳遞，如付款審批、經濟合同簽訂審批及員工假期報批等，以電子化系統作批覆或信息傳遞；
- 鼓勵員工多採用雙面打印，以及重用已經單面打印的文件；及
- 將生活垃圾分類收集，將可回收垃圾轉賣給回收站再利用。

A2 資源使用

為助益保護地球及將環境可持續性納入其業務職能及流程，本集團積極尋求提升營運效率的機會以減少資源使用。本集團亦密切監察資源的利用並就此方面的表現向高級管理層匯報。必要時，我們會採取適當的補救措施提升資源使用效率。

能源使用

本集團在能源使用方面主要為電力(含生產及生活用兩者)和柴油(生產過程中使用的燃料)。

除上文"**A1 排放物 – 溫室氣體及廢氣排放管理**"章節中提及的為減少溫室氣體及廢氣排放以達致節約柴油使用的措施外，本集團亦為達致更高能源利用率，於本報告期間，實施以下主要舉措以減少電力使用：

- 盡可能使用能源效益的電器；
- 辦公室空氣調節溫度控制在25攝氏溫度左右；及
- 關閉不使用的電器，或調校至節能模式。

The followings are the data on the electricity and diesel consumed by the Two Manufacturing Subsidiaries during the Reporting Period:

以下為兩家生產附屬公司於本報告期間電力和柴油使用數據：

Use of Resources 資源使用	Unit 單位	Period from 1 April 2020 to 31 March 2021 2020年4月1日至 2021年3月31日期間		Period from 1 April 2019 to 31 March 2020 2019年4月1日至 2020年3月31日期間	
		Volume Used 用量 Total 總計	Intensity* 密度* Per million HK\$ revenue 每百萬港元 收入	Volume Used 用量 Total 總計	Intensity* 密度* Per million HK\$ revenue 每百萬港元 收入
Energy 能源					
Electricity 電力	kWh 度	4,898,720	10,327.616	4,990,422	10,153.969
Diesel 柴油	metric ton 公噸 megajoules 兆焦耳	165 6,656,724	0.347 14,003.889	161 7,418,464	0.328 15,094.283

* Intensity is calculated by dividing the emission volume by the Group's total revenue during the Reporting Period.

* 密度的計算方式為本報告期間排放量除以本集團整體收入。

Use of water

The Two Manufacturing Subsidiaries use water supplied by the tap water supply company in China, mainly for the purpose of production and testing of pharmaceuticals, as well as daily life of the employees. The water quality complies with the national drinking water standards of the PRC, and the water supply is sufficient and fully meets our demand. For the effective use of water resources, the Group adopts water conservation management policy, where a variety of effective measures are carried out to reduce water consumption in its scope of operations, such as:

- Formulate "Water Running or Leakage" safety inspection measures to prevent waste of water resource;
- Install loop device for discharged wastewater generated by use of water during the production process, and reuse the cooling water and for greening and watering in the factories, which substantially save water resources and allow reuse to reduce emissions;
- Formulate water consumption standards for each production batch and request the production lines strictly follow and execute. The result is regarded as one of the major performance indicator during evaluation;
- Inspect and maintain water taps and water supply system promptly and periodically to prevent water leakage; and
- Carefully select production equipment, giving preference to water saving equipment.

用水

兩家生產附屬公司採用中國自來水公司供應水源，主要用於生產及試驗藥品，以及員工日常生活，水質符合中國國家飲用水標準，水源供應充足，完全滿足我們需求。為有效使用水資源，本集團採用節約用水管理政策，在其營運範圍內採取多種有效節約用水措施，比如：

- 制定“跑冒滴漏”安全檢查措施，杜絕浪費水資源；
- 對生產工藝用水產生的排放廢水安裝循環利用裝置，再次利用到冷卻用水循環及廠區綠化澆灌，大大節約水資源及重複利用減少排放；
- 為各生產品種批次制訂用水量標準，要求車間嚴格遵守及執行，並把執行結果納入主要績效考核；
- 對水龍頭及供水系統進行及時維修和定期檢查以防漏水；及
- 謹慎選擇生產設備，優先採用節水設備。

The followings are the data of the water used by the Two Manufacturing Subsidiaries during the Reporting Period:

以下為兩家生產附屬公司於本報告期間用水數據：

Use of Resources 資源使用	Unit 單位	Period from 1 April 2020 to 31 March 2021 2020年4月1日至 2021年3月31日期間		Period from 1 April 2019 to 31 March 2020 2019年4月1日至 2020年3月31日期間	
		Volume Used 用量 Total	Intensity* 密度* Per million HK\$ revenue 總計 每百萬港元 收入	Volume Used 用量 Total	Intensity* 密度* Per million HK\$ revenue 總計 每百萬港元 收入
Water 水	metric ton公噸	85,321	179.876	80,373	163.534

* Intensity is calculated by dividing the emission volume by the Group's total revenue during the Reporting Period.

* 密度的計算方式為本報告期間排放量除以本集團整體收入。

Use of packaging materials

The packaging materials used by the Group mainly include paper, plastic, glass and metal. For the procurement of product packaging materials, the Group has developed a comprehensive procurement management plan and quality control regulations. At the same time, the Group conducts strict on-site audit and quality assessment of raw materials in accordance with regulatory requirements. Only those suppliers that comply with both the relevant national regulations and the Group's quality control regulations are included in our qualified supplier scheme for procurement purpose. The Group also purchases packaging materials based on production plan and demand so as to reduce unnecessary consumption of resources.

According to the requirements of the Good Manufacturing Practice for Pharmaceutical Products, the Group has developed a series of processes and operating procedures for the use of "Raw Materials – Packaging Materials", including the standard operating procedures (SOP) for collecting and dispatching materials, the process yields as specified in the process regulations, the reasonable waste rate and the balance of materials, where the prescribed consumed and reported material wastes must be inspected on-site, verified and recorded properly, etc.

The followings are the data of the packaging materials used by the Two Manufacturing Subsidiaries during the Reporting Period:

包裝物料使用

本集團使用的包裝材料主要包括紙、塑膠、玻璃及金屬。針對產品包裝材料的採購，本集團制定了一套完整的採購管理方案及品質管制規定。同時，本集團對原材料供應商按照法規要求進行嚴格現場審計和品質評估，只有同時符合國家相關規定及本集團品質管制規定的供應商，方會納入合格供應商體系。本集團亦會根據生產計劃按需採購，以減少不必要的資源使用。

根據《藥品生產質量管理規範》要求，本集團制定一系列有關“原材料-包裝物料”使用的工藝規程、操作規程等制度，包括領發料的標準操作規程，工藝規程規定的各工序生產得率、合適損耗率和物料平衡，規定消耗損耗和報廢物料必須得到現場品質檢驗、確認並有記錄等。

以下為兩家生產附屬公司於本報告期間包裝物料使用數據：

Use of Resources 資源使用	Unit 單位	Period from 1 April 2020 to 31 March 2021 2020年4月1日至 2021年3月31日期間		Period from 1 April 2019 to 31 March 2020 2019年4月1日至 2020年3月31日期間	
		Volume Used 用量 Total	Intensity* 密度* Per million HK\$ revenue 總計 每百萬港元 收入	Volume Used 用量 Total	Intensity* 密度* Per million HK\$ revenue 總計 每百萬港元 收入
Packaging materials 包裝物料	metric ton公噸	1,101	2.322	1,670	3.399

* Intensity is calculated by dividing the emission volume by the Group's total revenue during the Reporting Period.

* 密度的計算方式為本報告期間排放量除以本集團整體收入。

A3 The Environment and Natural Resources
Air quality

In order to improve air quality, the Group aims to reduce air emissions generated from its production by green initiatives. The Group is committed to fulfilling and complying with the regime of smoking prevention and control requirements.

B. SOCIAL

B1 Employment
Labour practices

The Group has always adhered to its mission of “Nurture Talents and Strengthen the Team” in human resources management. With this mission and as an equal opportunity employer, the Group is committed to provide a working environment without discrimination and inequality, where safety and health of employees are being protected. Opportunities for continuous development and training will be provided to employees as well.

The Group has production bases and/or offices in China, Hong Kong and Australia with employees hired. The Group strictly abides by relevant local laws and regulations in relation to labour, where the relevant laws and regulations that have significant impact on the Group mainly include the following:

- Labor Law of the PRC ;
- Labor Contract Law of the RPC ;
- Employment Ordinance of Hong Kong; and
- National Employment Standards of Australia.

During the Reporting Period, to the best of our knowledge and information, the Group did not find and was not aware of any incidents of non-compliance to the abovementioned laws and regulations in relation to employment.

To ensure the employees follow professional and ethical practices, the Group has developed clear work processes with robust control mechanisms which have been clearly communicated to all employees. Certain policies governing employees’ affairs, such as payroll, attendance, termination, are clearly set out in staff employment contracts or appointment letters and complied strictly.

The Group also aims to promote the diversity of workforce, including in terms of age, gender and nationality, as well as a culture of equal opportunity.

A3 環境及天然資源
空氣質素

為幫助改善空氣質素，本集團旨在透過綠色環保措施減少其生產產生的空氣排放量。本集團致力於履行並遵守預防及控制黑煙制度的規定。

B. 社會

B1 僱傭
勞工常規

本集團於人力資源管理，一直遵循“知人善用、強化團隊”的使命。藉著此使命及作為平等機會僱主，本集團致力提供一個沒有歧視及不平等的工作環境，而員工安全及健康會受到保障，亦會為員工提供持續發展及培訓的機會。

本集團在中國、香港及澳大利亞設有生產基地及/或辦事處，並聘有員工。本集團嚴格遵守當地勞工法律及規例，當中對本集團有重大影響的相關法律及規例主要包括下列所述：

- 《中華人民共和國勞動法》；
- 《中華人民共和國勞動合同法》；
- 《香港僱傭條例》；及
- 《澳大利亞國家就業標準》。

於本報告期間，據我們所知及信息，本集團並未發現及察覺到任何違反上述有關勞工的法例及規例之情形。

為確保員工能遵從專業及道德常規，本集團已制訂具備穩健監控機制的明確工作流程，並已清晰地傳達給全體員工。若干規管僱員事務的政策，如薪資、出席及終止聘用，已清楚載於勞動合同或僱員委任函件中，並嚴格遵守。

本集團亦旨在提升員工多樣性，包括年齡、性別及國籍以及平等機會文化。

Employee Benefits

The Group cares about the physical and mental health development of the employees and is committed to taking care of every employee. The Group regularly organizes various after-work activities in order to promote networking among colleagues and increase the employees' sense of belonging to the Group.

The management regularly reviews the Group's remuneration policy in relation to relevant market standards.

B2 Health and Safety **Workplace health and safety**

In addition to complying with the labour laws and regulations as mentioned above in the section B1, the Group also strictly abides by its relevant local laws and regulations in relation to workplace health and safety, where the relevant laws and regulations that have a significant impact on the Group mainly include the following:

- Law of the PRC on the Prevention and Control of Occupational Diseases;
- Production Safety Law of the PRC; and
- Regulation on Work-Related Injury Insurances of the PRC.

During the Reporting Period, to the best of our knowledge and information, the Group did not find and was not aware of any incidents of non-compliance to the laws and regulations in relation to workplace health and safety as mentioned above.

The Group has established a set of policies which is focused on maintaining a healthy and safe working environment, and which includes the following requirements:

- The facilities operated by employees should meet health and safety standards;
- Expert advices should be obtained to identify health and safety risks in the operations and the corresponding mitigating actions that should be taken;
- Relevant information and training should be provided to employees in respect of risks to their health and safety which may arise in their work;
- Conduct annual health checkups for employees each year and arrange special occupational health checks for relevant personnel; and

員工福利

本集團關心員工的精神健康和身心發展，致力照顧每位員工的福祉。本集團定期舉辦不同工餘活動，促進同事之間的聯誼交流，並藉此增加員工對本集團的歸屬感。

本集團的管理層就有關市場標準定期檢討本集團的薪酬政策。

B2 健康與安全 **工作環境健康與安全**

除遵守上述B1章節勞工法律及規例外，本集團亦嚴格遵守其當地之有關工作環境健康及安全的法律及規例，當中對本集團有重大影響的相關法律及規例主要包括下列所述：

- 《中華人民共和國職業病防治法》；
- 《中華人民共和國安全生產法》；及
- 《中華人民共和國工傷保險條例》。

於本報告期間，據我們所知及信息，本集團並未發現及察覺到任何違反上述有關工作環境健康及安全的法例及規例之情形。

本集團已訂立一套專注於維持健康與安全工作環境的政策，當中包括下列規定：

- 操作的設施應符合健康及安全標準；
- 應取得專家的意見以識別營運中的健康及安全風險，並應採取相應的降低風險措施；
- 就僱員工作中可能產生的健康及安全風險應向其提供有關資料及培訓；
- 安排員工進行一年一次的健康體檢，並為相關崗位人員安排了特定職業健康檢查；及

- The Group provides medical insurance coverage to its staff. Employees also can enjoy concessionary consultation and treatments in the Group's TCM clinics.

The Group has established a mechanism for monitoring occupational health and safety, as well as procedures for dealing with related risks. Employees are invited to participate in the determination of occupational health and safety precautionary measures. Accident reporting and investigation procedures have also been adopted for the follow-up of any health and safety incidents.

B3 Development and Training **Employee development and training**

The Group strives to promote the long-term development of its employees by providing learning opportunities that broaden their skills and make them to be valuable assets to the Group.

Various employee training programs and seminars held by internal/external organisations are offered to employees, including in the areas of finance, governance, rules and regulations, supervisory and managerial skills, as well as various technical training courses relating to their respective job duties.

During the Reporting Period, we conducted several production safety educations, fire prevention trainings and emergency fire drills to enhance the employees' familiarity with the safety knowledge, which significantly improved the awareness of all employees about occupational safety, strengthened the protection to employees and reduced the chances of accidents. The Group also conducts safety education and training for each on-board new employee, whereby only those who passed the relevant examination will be employed.

The Group also actively organized outdoor development training in order to enhancing employees' awareness of social environmental protection.

B4 Labour Standards **Anti-child and forced labour**

In addition to complying with the labour laws and regulations as mentioned above in the section B1, the Group also strictly abides by its relevant local laws and regulations in relation to child and forced labour, where the relevant laws and regulations that have a significant impact on the Group mainly include the following:

- Provisions on the Prohibition of Using Child Labor of the PRC; and

- 本集團為員工提供醫療保險保障。員工亦可於集團旗下的中醫診所享用諮詢及診療優惠。

本集團已建立監察職業健康及安全的機制，以及處理有關風險的程序，邀請僱員參與職業健康及安全預防措施的釐定。就跟進任何健康及安全事故，本集團亦採取事故報告及調查程序。

B3 發展及培訓 **僱員發展及培訓**

本集團致力於向其員工提供拓展技能的學習機會，藉以推動員工的長期發展，使彼等成為本集團的寶貴資產。

本集團向員工提供各種由內/外部團體舉辦的員工培訓項目及研討會，包括金融、管治、規則及規例、監督及管理技能，以及與彼等各自的工作職責有關的各種技術培訓課程等領域。

本報告期內，我們內部多次開展生產安全教育、防火培訓、以及消防應急演練，加強員工對安全知識的熟知，從而顯著提高了全體員工對職業安全的認知，加強員工保障、以及減低意外事故機會。本集團亦對每一位入職的新員工進行安全教育培訓，就有關考試合格的員工方能上崗。

本集團亦積極組織員工參加戶外拓展培訓，增強員工對社會環境保護的意識。

B4 勞工準則 **禁止童工及強制性勞動**

除遵守上述B1章節勞工法律及規例外，本集團亦嚴格遵守其當地之有關童工或強制性勞動的法律及規例，當中對本集團有重大影響的相關法律及規例主要包括下列所述：

- 《中華人民共和國禁止使用童工規定》；及

- Law of the PRC on the Protection of Minors.

During the Reporting Period, to the best of our knowledge and information, the Group did not find and was not aware of any incidents of non-compliance to the relevant laws and regulations in relation to child and forced labour as mentioned above.

The Group strictly prohibits the use of child and forced labour in the Group, and is committed to create a working environment that fully respects human rights.

In addition to having well-established recruitment processes requiring background checks on candidates and reporting on exceptions found, the Group also performs regular reviews and inspections to detect the existence of any child or forced labour in the operations.

Operating Practices

B5 Supply Chain Management

The Group's medicine raw materials, medicine, Chinese herbal medicines and traditional Chinese medicine decoction pieces are mainly sourced from suppliers in mainland China, while healthcare products are mainly from China and Australia.

When the Group conducts purchases, the selected item must be either manufactured by an enterprise who has passed the Good Manufacturing Practice (GMP) verification or wholesaled through a corporation with the Good Supply Practice (GSP) certificate.

When selecting suppliers, the Group considers factors such as the operation and production qualification, product quality, market prospect, service quality, environmental protection concept, business ethics and social responsibility, etc. The Group is inclined to select socially responsible suppliers and hopes to implement green supply chain practices in the Group's business. The Group is committed to creating a mutually beneficial and win-win partnership with the suppliers.

B6 Product Responsibility *Product health and safety and labelling*

The Group strictly abides by its relevant local laws and regulations in relation to product health and safety and labelling, where the relevant laws and regulations that have a significant impact on the Group mainly include the following:

- Medicinal Product Administration Law of the PRC;

- 《中華人民共和國未成年人保護法》。

於本報告期間，據我們所知及信息，本集團並未發現及察覺到任何違反上述有關童工或強制性勞動的法例及規例之情形。

本集團嚴格禁止在本集團使用童工及強制性勞動，並致力於創建一個完全尊重人權的工作環境。

除已建立應聘者背景審查的完善招聘流程及例外情況彙報程序外，本集團亦定期進行審查及檢查，以防止經營中存在的任何童工或強制性勞動。

營運慣例

B5 供應鏈管理

本集團醫藥原材料及成藥、中藥材及中藥飲片主要由中國大陸供應商供應；而保健產品則主要來自中國及澳大利亞。

本集團進行採購時，所選品種必須是通過《生產質量管理規範》(GMP)認證的企業生產，或通過《經營質量管理規範》(GSP)認證的經營企業批發。

本集團在選擇供應商時所考慮因素包括企業的運營及生產資質、產品品質、市場前景、供應商服務質素、環保理念、商業倫理及社會責任等。本集團傾向於選擇具有社會責任感的供應商，並希望將綠色環保踐行於本集團業務的供應鏈環節。本集團致力於打造與供應商互利共贏的合作關係。

B6 產品責任 *產品健康與安全以及標籤*

本集團嚴格遵守其當地之有關產品健康與安全以及標籤的法律及規例，當中對本集團有重大影響的相關法律及規例主要包括下列所述：

- 《中華人民共和國藥品管理法》；

- Regulations for the Implementation of the Drug Administration Law of the PRC;
- Measures for the Administration of Drug Registration ;
- Good Manufacturing Practices for Pharmaceutical Products (National and local regions standards, if any);
- Good Supply Practice for Pharmaceutical Products (National and local regions standards, if any);
- Provisions on the Administration of Pharmaceutical Directions and Labels (National and local regions standards, if any);
- Pharmacopoeia of China;
- Notice of Strengthening the Supervision and Administration of TCM Decoction Pieces;
- National Pharmaceutical Packaging Standard; and
- Law of the PRC on Protection of Consumer Rights and Interests.

During the Reporting Period, to the best of our knowledge and information, the Group did not find and was not aware of any incident of non-compliance to the above laws and regulations in relation to product health and safety and labelling.

The medical products promoted and sold by the Group are all registered with the local authorities. Imported products are further supported by test and inspection report issued by the import ports or the place of origin.

The medicines, healthcare products, Chinese medicinal materials and TCM decoction pieces sold by the Group must be verified by a third-party testing agency to ensure the content, heavy metals, pesticide residues, etc., are complied with standards.

The major subsidiaries of the Group engage in the manufacture and sales of pharmaceutical or TCM products have obtained the latest GMP and GSP certifications. As for product storage, the Group has reasonable storage arrangement according to the quality characteristics of the products, which is equipped with warehouse, air conditioning, and facilities for shading, ventilation, anti-moisture, pest control, rodent control and safety monitoring, etc.

Furthermore, the Group's warehouse is equipped with 24-hour automatic temperature and humidity monitoring system to maintain a good storage status of the products. Before delivery, the Group will check the products to ensure packaging integrity. We have dedicated departments responsible for product health and safety, as well as the compliance of labelling, and strictly adhere to product specifications and local government's regulations. During the Reporting Period, there was no recall of drugs due to health and safety issues.

- 《中華人民共和國藥品管理法實施條例》；
- 《藥品註冊管理辦法》；
- 《藥品生產質量管理規範》(國家及當地地區標準，如有)；
- 《藥品經營質量管理規範》(國家及當地地區標準，如有)；
- 《藥品說明書和標籤管理規定》(國家及當地地區標準，如有)；
- 《中國藥典》；
- 《關於加強中藥飲片包裝監督管理的通知》；
- 《國家藥包材標準》；及
- 《中華人民共和國消費者權益保護法》。

於本報告期間，據我們所知及信息，本集團並未發現及察覺到任何違反上述有關產品健康與安全以及標籤的法律及規例之情形。

本集團推廣及銷售的醫藥藥品均已向當地政府部門註冊；進口產品更需要獲得進口口岸的檢測報告或原產地的檢驗報告。

本集團所銷售的藥品、保健品、中藥材以及中藥飲片，均須要通過第三方檢測機構檢定，確定含量、重金屬、農藥殘留量等符合標準。

本集團從事藥品或中醫藥產品生產或銷售的主要附屬公司均已獲得最新版《GMP》及《GSP》認證。在產品儲存方面，本集團根據產品的質量特性對產品進行合理的儲存，配備相應的庫房及空調，同時配有避光、遮光、通風、防潮、防蟲、防鼠、安全監控等設施設備。

另配倉庫有24小時溫濕度自動監測系統，確保產品保持良好的儲存狀態。本集團在發貨前均要求進行出庫覆核，確保包裝完整性。我們設有專責部門，負責產品的健康與安全，以及標籤的合規事宜，一律嚴格遵守產品說明書及當地政府相關規定。本報告期間，本集團沒有涉及因健康與安全問題發生的藥品召回事件。

Customer privacy and data protection

The Group values and respects the customer privacy and data protection. As a clinical service provider, the Group handles a number of sensitive personal information of the patients. The privacy of customers and patients are vital to the Group. Aside from abiding the relevant laws and regulations, customer privacy protection allows the Group to gain customers' trust, and maintain brand reputation. In view of this, the Group strives to protect the customers' and patients' privacy by developing internal guidelines. The employees are required to follow the listed procedure to handle the personal information of the customers and patients properly and prohibit any unauthorized access to the collected data.

B7 Anti-corruption

Anti-corruption and money laundering

The Group strictly abides by its relevant local laws and regulations in relation to anti-corruption and money laundering, where the relevant laws and regulations that have a significant impact on the Group mainly include the following:

- Criminal Law of the PRC;
- Anti-corruption Law of the PRC ;
- Prevention of Bribery Ordinance of Hong Kong; and
- Anti-money Laundering and Counter-Terrorism Financing Act 2006 of Australia.

During the Reporting Period, to the best of our knowledge and information, the Group did not find and was not aware of any incidents of non-compliance to the above relevant laws and regulations in relation to anti-corruption and money laundering.

The Group has in place a number of policies addressing anti-corruption (such as acceptance of gifts and conflicts of interest), which provide guidance to employees in this area. The Group has also established policies and procedures to deal with money laundering in its operations.

In addition, the Group has established prevention system by setting up communication channels for faults and anti-corruption reporting. The whistle-blowing system can handle any breach of laws and regulations.

Trainings on anti-corruption and anti-money laundering are provided to employees in order to raise their awareness of the code of conduct as well as related procedures and guidelines.

During the Reporting Period, no legal case regarding corruption was brought against the Group or its employees.

客戶私隱及資料保護

本集團重視並尊重客戶私隱及資料保護，作為臨床服務提供者，本集團處理許多應診者的個人資料。客戶和應診者的隱私對本集團至關重要。除遵守相關法律法規外，客戶私隱保護亦使本集團獲得客戶的信任，並保持其品牌聲譽。有鑑於此，本集團通過制定內部守則以努力保障客戶和應診者的私隱。員工必須按照列出的程序妥善處理客戶和應診者的個人資料，並禁止未經授權的員工索取有關資料。

B7 反貪污

反貪污及洗黑錢

本集團嚴格遵守其當地之有關反貪污及洗黑錢的法律及規例，當中對本集團有重大影響的相關法律及規例主要包括下列所述：

- 《中華人民共和國刑法》；
- 《中華人民共和國反腐敗法》；
- 《香港防止賄賂條例》；及
- 《澳大利亞2006年反洗黑錢和反恐融資法》。

於本報告期間，據我們所知及信息，本集團並未發現及察覺到任何違反上述有關反貪污及洗黑錢的法律及規例之情形。

本集團現有多個解決反貪污的政策（如收受禮物及利益衝突），為僱員在這方面提供指引。本集團亦已制訂政策及程序以應對業務的洗黑錢活動。

此外，本集團透過訂立申報及反貪污的溝通渠道，成立防範機制，舉報機制可應付任何違法及違規行為。

為提高各級僱員的行為守則以及有關程序及指引意識，本集團向僱員提供有關反貪污及反洗黑錢的培訓。

於本報告期間，並無對本集團或其僱員提出的貪污訴訟案件。

Community

B8 Community Investment

Community programs and donation

Upholding the mission of “Care for a Better World”, the Group and Mr. Fang Wen Quan, the Company’s Chairman and Managing Director, have been deeply devoting to community over the years to show their greater commitments to community services, including but not limited to donations to support the poverties, education and talent development, healthcare, scientific research, environmental protection, culture and arts.

The Group actively performs corporate social responsibilities and jointly organized public welfares with different social institutions. Meanwhile, it encourages its employees to reward the community and society by active participations in various public welfare activities. During the Reporting Period, the Group and its employees participated in the following community charity campaign and activities:

- In Zhuhai, the Group supported the event of “Guangdong Poverty Relief Day” and participated in a number of community charity activities;
- In Kunming, the labour union of Meng Sheng Pharmaceutical actively participated in the “Delivery of Warmth” activity, that is, showing consolations and cares to the workers in difficult living conditions during various festivals;
- In Guangdong, the Group supported the college-enterprise cooperation programme, participated in campus recruitment fairs organized by Guangdong University of Technology, Guangxi University of Chinese Medicine, Guangdong Lingnan Institute of Technology, Guangdong Ocean University, Hunan University of Chinese Medicine, Zhuhai Health School, Zhaoqing Medical College, Guangzhou Pharmaceutical Vocational School, Guangxi Agricultural Vocational College, and provided more than 50 internship positions for students;

Fighting the virus together

Adhering to the mission of “Tianda for Health!”, the Group actively joins the world in the fight against the pandemic by leveraging the unique strengths of Chinese medicine.

- The Group organized “Anti-Epidemic Formula 1”, Chinese Medicine Healthcare Welfare events in communities in Guangdong-Hong

社區

B8 社區投資

社區計劃及捐款

秉承“關心社會，共同發展”的使命，本集團及本公司董事長兼董事總經理方文權先生多年來致力回饋社會、熱誠資助社會公益，包括但不限於捐資扶貧、教育和人才發展、醫療衛生、科學研究、環境保護、文化藝術等。

本集團積極履行企業社會責任，與不同社會機構共同經營公益事業，同時鼓勵員工走上社會，深入社區，參與各類公益活動，以實際行動回饋社會。於本報告期間，本集團及其員工參與了以下社區公益及活動：

- 在珠海，本集團響應“廣東扶貧濟困日”活動，並參與多項社區慈善工作；
- 在昆明，盟生藥業工會積極參與“送溫暖”慰問活動，在不同節日中向困難職工送上關愛；
- 在廣東，本集團支持校企合作人才合作計劃，參加廣東工業大學、廣西中醫藥大學、廣東嶺南職業技術學院、廣東海洋大學、湖南中醫藥大學、珠海衛校、肇慶醫學高等專科學校、廣州市醫藥職業學校、廣西農業職業技術學院等院校舉辦的校園招聘，並先後為院校學生提供了逾50多個實習崗位；

疫境同行

新冠肺炎疫情持續肆虐，本集團秉承“您的健康是天大的事”的使命，發揮中醫藥優勢，積極支援全球抗疫。

- 本集團深入粵港澳多個社區，舉辦「抗疫一方」中醫義診活動，為逾千名市民義診及健康諮詢服

Kong-Macao Greater Bay Area and provided complimentary free medical checkup and health consultant services to over 1000 citizens. Also, “Anti-Epidemic Formula 1”, an herbal prescription developed by the Group and a TCM expert team, was offered to help them to fight against COVID-19.

- The Group offered “Anti-Epidemic Formula 1” to its employees for enhancing their physical fitness in the fight against the virus;
- Following the development of “Anti-Epidemic Formula 1” (for prevention), the Group further developed “Anti-Epidemic Formula 2” (for remedy) and “Anti-Epidemic Formula 3” (for rehabilitation) in collaboration with authoritative Chinese medicine expert teams and contributed to the global fight against the epidemic; and
- The Group adopted different measures in order to ensure the safety and health of its employees, including introducing staggered working hours, maintaining strict cleaning and disinfection management, arranging in-house education to enhance the awareness of epidemic prevention, and encouraging employees to get vaccination.

Chinese Medicine Promotion

The Group values the development and the inheritance of TCM, striving to promote the culture of TCM.

The Group organized various TCM education seminars and activities with charity organizations for parents and children allowing them to understand and experience the culture of TCM, cultivating children’s interest in TCM and promoting the inheritance of TCM..

AWARDS AND RECOGNITIONS

With the efforts with the Group, during the Reporting Period, the Group received the “Sustainable Development of Society (Health and Wellness) -The Greater Bay Area-Sustainable Business Award” jointly held by Metro Finance and Hong Kong Quality Assurance Agency and were awarded the “Caring Company” logo by the Hong Kong Council of Society Services.

The awards demonstrate the Group’s efforts in fulfilling corporate social responsibility and promoting the community sustainable developments are well recognized and affirmed by the public.

務，並免費贈送由本集團與中醫藥專家組研定的「抗疫一方」草藥方，幫助三地市民預防新冠肺炎；

- 本集團為員工提供「抗疫一方」，輔助同事們提升體質，預防病毒；
- 繼「抗疫一方」（預防方），本集團再會同中國內地中醫藥權威專家研定形成「抗疫二方」（治療方）及「抗疫三方」（康復方）中藥抗疫方劑，為全球抗疫作出貢獻；及
- 本集團採取不同防疫措施以確保員工的安全和健康，當中包括：准許辦公室人員錯峰上班、實施嚴格清潔消毒管理、安排內部教育提高防疫意識，以及鼓勵員工接種疫苗等。

推動中醫藥發展

本集團重視中醫藥發展及傳承，致力弘揚中醫藥文化。

本集團與公益機構合作，舉辦了不同中醫親子教育講座及活動，為家長和孩子提供了認識及接觸中醫藥文化並體驗中醫藥的機會，培養小朋友對中醫藥的興趣，推動中醫藥傳承。

獎項與嘉許

在本集團上下共同努力下，於本報告期先後獲得由新城財經台及香港品質保證局頒發的「灣區·企業可持續發展大獎(良好健康與福祉)」以及獲頒香港社會服務聯會的「商界展關懷」標誌。

獎項證明了公眾對本集團履行企業社會責任、促進社區持續發展所付出努力的認同以及肯定。

The Group will continue to fulfill its corporate social responsibilities by caring for the community and employees, enhancing the health and wellness of the general public as well as promoting the development of Chinese medicine, striving to create long-term social value.

Stakeholders' Feedback

In addition to reporting our achievements in this ESG Report, we welcome stakeholders' feedback regarding our ESG approach and performance. Please share your views with us through the following:-

Correspondence address:	Hong Kong Office, Suites 2405-2410, 24th Floor CITIC Tower No. 1 Tim Mei Avenue Central, Hong Kong
Telephone:	(852) 2545 3313
Facsimile:	(852) 2541 6558
E-mail:	ir@tianda.com

本集團將繼續貫徹履行企業社會責任，關心社會及員工、提升全民健康水平、推動中醫藥發展，致力創造更長遠的社會價值。

持份者的意見回饋

在本環境、社會及管治報告匯報成果之餘，本集團亦歡迎各持份者就本集團的環境、社會及管治方針與表現發表意見。請透過下列方式與本集團分享寶貴意見：-

郵寄地址	香港辦公室 香港中環 添美道1號 中信大廈 24樓2405-2410室
電話：	(852) 2545 3313
傳真：	(852) 2541 6558
電郵：	ir@tianda.com

您的健康是天大的事
TIANDA FOR HEALTH